Literature DB >> 11896157

The mitochondrial toxin 3-nitropropionic acid induces striatal neurodegeneration via a c-Jun N-terminal kinase/c-Jun module.

Marta Garcia1, Peter Vanhoutte, Christiane Pages, Marie-Jo Besson, Emmanuel Brouillet, Jocelyne Caboche.   

Abstract

Impairments in mitochondrial energy metabolism are thought to be involved in most neurodegenerative diseases, including Huntington's disease (HD). Chronic administration of 3-nitropropionic acid (3-NP), a suicide inhibitor of succinate dehydrogenase, causes prolonged energy impairments and replicates most of the pathophysiological features of HD, including preferential striatal degeneration. In this study, we analyzed one of the mechanisms that could account for this selective 3-NP-induced striatal degeneration. In chronically 3-NP-infused rats, the time course of motor behavioral impairments and histological abnormalities was determined. Progressive alterations of motor performance occurred after 3 d. By histological analysis and terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end-labeling staining, we found a selective neurodegenerescence in the striatum, occurring first in its dorsolateral (DL) part. Activation of c-Jun N-terminal kinase (JNK) was analyzed from brain sections of these rats, using immunocytochemical detection of its phosphorylated form. Activation of JNK occurred progressively and selectively in the DL of the striatum and was followed by c-Jun activation and expression in the same striatal region. To elucidate the role of the JNK/c-Jun module in 3-NP-induced striatal degeneration, we then used primary striatal neurons in culture, in which we replicated neuronal death by application of 3-NP. We found strong nuclear translocation of activated JNK that was rapidly followed by phosphorylation of the transcription factor c-Jun. Overexpression of a dominant negative version of c-Jun, lacking its transactivation domain and phosphorylation sites for activated JNK, completely abolished 3-NP-induced striatal neurodegeneration. We thus conclude that a genetic program controlled by the JNK/c-Jun module is an important molecular event in 3-NP-induced striatal degeneration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11896157      PMCID: PMC6758250     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  57 in total

1.  Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release.

Authors:  J Whitfield; S J Neame; L Paquet; O Bernard; J Ham
Journal:  Neuron       Date:  2001-03       Impact factor: 17.173

2.  Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization.

Authors:  A Sawa; G W Wiegand; J Cooper; R L Margolis; A H Sharp; J F Lawler; J T Greenamyre; S H Snyder; C A Ross
Journal:  Nat Med       Date:  1999-10       Impact factor: 53.440

Review 3.  The c-Jun transcription factor--bipotential mediator of neuronal death, survival and regeneration.

Authors:  T Herdegen; P Skene; M Bähr
Journal:  Trends Neurosci       Date:  1997-05       Impact factor: 13.837

Review 4.  Excitatory amino acids as a final common pathway for neurologic disorders.

Authors:  S A Lipton; P A Rosenberg
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

5.  Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation.

Authors:  A Behrens; M Sibilia; E F Wagner
Journal:  Nat Genet       Date:  1999-03       Impact factor: 38.330

6.  Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand.

Authors:  Y Morishima; Y Gotoh; J Zieg; T Barrett; H Takano; R Flavell; R J Davis; Y Shirasaki; M E Greenberg
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

Review 7.  Role of nitric oxide in neurodegenerative diseases.

Authors:  J B Schulz; R T Matthews; M F Beal
Journal:  Curr Opin Neurol       Date:  1995-12       Impact factor: 5.710

8.  Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death.

Authors:  H Le-Niculescu; E Bonfoco; Y Kasuya; F X Claret; D R Green; M Karin
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

9.  NMDA receptor involvement in toxicity to dopamine neurons in vitro caused by the succinate dehydrogenase inhibitor 3-nitropropionic acid.

Authors:  G D Zeevalk; E Derr-Yellin; W J Nicklas
Journal:  J Neurochem       Date:  1995-01       Impact factor: 5.372

10.  Lasting N-terminal phosphorylation of c-Jun and activation of c-Jun N-terminal kinases after neuronal injury.

Authors:  T Herdegen; F X Claret; T Kallunki; A Martin-Villalba; C Winter; T Hunter; M Karin
Journal:  J Neurosci       Date:  1998-07-15       Impact factor: 6.167

View more
  22 in total

1.  Sodium selenite protects from 3-nitropropionic acid-induced oxidative stress in cultured primary cortical neurons.

Authors:  Dirleise Colle; Danúbia Bonfanti Santos; Viviane de Souza; Mark William Lopes; Rodrigo Bainy Leal; Patricia de Souza Brocardo; Marcelo Farina
Journal:  Mol Biol Rep       Date:  2018-12-03       Impact factor: 2.316

2.  pH as a biomarker of neurodegeneration in Huntington's disease: a translational rodent-human MRS study.

Authors:  Myriam M Chaumeil; Julien Valette; Céline Baligand; Emmanuel Brouillet; Philippe Hantraye; Gilles Bloch; Véronique Gaura; Amandine Rialland; Pierre Krystkowiak; Christophe Verny; Philippe Damier; Philippe Remy; Anne-Catherine Bachoud-Levi; Pierre Carlier; Vincent Lebon
Journal:  J Cereb Blood Flow Metab       Date:  2012-02-29       Impact factor: 6.200

Review 3.  Role of manganese in neurodegenerative diseases.

Authors:  Aaron B Bowman; Gunnar F Kwakye; Elena Herrero Hernández; Michael Aschner
Journal:  J Trace Elem Med Biol       Date:  2011-10-01       Impact factor: 3.849

Review 4.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

Review 5.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

6.  Mitochondrial retrograde signalling in neurological disease.

Authors:  Lucy Granat; Rachel J Hunt; Joseph M Bateman
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2020-05-04       Impact factor: 6.237

7.  Movement sequencing in Huntington disease.

Authors:  Nellie Georgiou-Karistianis; Jeffrey D Long; Spencer G Lourens; Julie C Stout; James A Mills; Jane S Paulsen
Journal:  World J Biol Psychiatry       Date:  2014-03-28       Impact factor: 4.132

8.  Isolation of intrinsically active (MEK-independent) variants of the ERK family of mitogen-activated protein (MAP) kinases.

Authors:  Vered Levin-Salomon; Konstantin Kogan; Natalie G Ahn; Oded Livnah; David Engelberg
Journal:  J Biol Chem       Date:  2008-10-01       Impact factor: 5.157

Review 9.  Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases.

Authors:  A Cristina Rego; Catarina R Oliveira
Journal:  Neurochem Res       Date:  2003-10       Impact factor: 3.996

10.  Early epigenomic and transcriptional changes reveal Elk-1 transcription factor as a therapeutic target in Huntington's disease.

Authors:  Ferah Yildirim; Christopher W Ng; Vincent Kappes; Tobias Ehrenberger; Siobhan K Rigby; Victoria Stivanello; Theresa A Gipson; Anthony R Soltis; Peter Vanhoutte; Jocelyne Caboche; David E Housman; Ernest Fraenkel
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.